Hu5F9-G4 clinical trial update

Results from the first part of a clinical trial testing the Hu5F9-G4 antibody treatment were presented at the American Society of Clinical Oncology (ASCO) annual meeting in June 2018.

This part of the trial aimed to find the best dose of Hu5F9-G4 in combination with the antibody treatment rituximab for people with B-cell lymphomas.

When the results were analysed, 22 people with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma had been treated in the trial. These people had lymphoma that was not responding to standard treatments or who couldn’t have standard treatment. On average, they had received four previous courses of treatment before taking part in this trial.

Different doses were tested in this part of the trial and the results were encouraging:

Even the highest dose tested was generally well tolerated. The most common side effects were reported as temporary anaemia (low red blood cells) that got better after treatment, and flu-like symptoms including chills, headaches and fevers.

Around half of the people treated in the trial responded to treatment.

The trial is ongoing so it remains to be seen whether the response is long-lasting but at least one person has stayed in remission for over a year so far.

The trial is now testing the best dose selected from part 1 of the trial and is open to new participants. Find out more about the trial at Lymphoma TrialsLink.

Read the abstract presented at ASCO.